Pages that link to "Q37920162"
The following pages link to Dopaminergic mechanisms in idiopathic and drug-induced psychoses (Q37920162):
Displaying 50 items.
- Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects (Q22248075) (← links)
- Sigma1 receptor antagonists determine the behavioral pattern of the methamphetamine-induced stereotypy in mice (Q24615155) (← links)
- Neurologic manifestations of chronic methamphetamine abuse (Q24624506) (← links)
- Animal models of schizophrenia: a critical review (Q24674909) (← links)
- Dual diagnosis: a review of etiological theories (Q28287738) (← links)
- A neurobiological basis for substance abuse comorbidity in schizophrenia (Q28347063) (← links)
- Apomorphine and the dopamine hypothesis of schizophrenia: a dilemma? (Q28366409) (← links)
- Paranoid psychosis induced by oxymetazoline nasal spray (Q28378465) (← links)
- Schizophrenia, “Just the Facts” 6. Moving ahead with the schizophrenia concept: From the elephant to the mouse (Q28727394) (← links)
- Sex-specific brain deficits in auditory processing in an animal model of cocaine-related schizophrenic disorders (Q30436400) (← links)
- Gestational methylazoxymethanol acetate administration: a developmental disruption model of schizophrenia (Q30478274) (← links)
- A sex- and region-specific role of Akt1 in the modulation of methamphetamine-induced hyperlocomotion and striatal neuronal activity: implications in schizophrenia and methamphetamine-induced psychosis (Q30572456) (← links)
- Abnormal regulation of corticopetal cholinergic neurons and impaired information processing in neuropsychiatric disorders (Q33544991) (← links)
- Increased dopamine transmission in schizophrenia: relationship to illness phases (Q33679807) (← links)
- Symptom provocation studies in psychiatric disorders: scientific value, risks, and future (Q33760635) (← links)
- Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies (Q33833648) (← links)
- Acute psychological and physiological effects of MDMA ("Ecstasy") after haloperidol pretreatment in healthy humans (Q33907331) (← links)
- Iboga interactions with psychomotor stimulants: panacea in the paradox? (Q33998417) (← links)
- Motivational responses to natural and drug rewards in rats with neonatal ventral hippocampal lesions: an animal model of dual diagnosis schizophrenia (Q34056092) (← links)
- Interpreting the association between cannabis use and increased risk for schizophrenia (Q34439127) (← links)
- Drug-induced psychosis: how to avoid star gazing in schizophrenia research by looking at more obvious sources of light (Q34509725) (← links)
- Psychosis pathways converge via D2high dopamine receptors (Q34540180) (← links)
- Effects of a selective Y2R antagonist, JNJ-31020028, on nicotine abstinence-related social anxiety-like behavior, neuropeptide Y and corticotropin releasing factor mRNA levels in the novelty-seeking phenotype (Q34988146) (← links)
- Dopamine in the history of the schizophrenic brain: recent contributions of brain-imaging studies (Q35236303) (← links)
- Integrated services for treatment of schizophrenic substance abusers: demographics, symptoms, and substance abuse patterns (Q35531488) (← links)
- Pharmacologic challenge in ERP research (Q35670925) (← links)
- Long-term effects of juvenile nicotine exposure on abstinence-related social anxiety-like behavior and amygdalar cannabinoid receptor 1 (CB1R) mRNA expression in the novelty-seeking phenotype (Q35690700) (← links)
- Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function (Q35745285) (← links)
- DNA-hydrolysing activity of IgG antibodies from the sera of patients with schizophrenia (Q35779904) (← links)
- Dopamine's Actions in Primate Prefrontal Cortex: Challenges for Treating Cognitive Disorders (Q35795738) (← links)
- Do child abuse and maltreatment increase risk of schizophrenia? (Q36024169) (← links)
- Pretreatment or Posttreatment with Aripiprazole Attenuates Methamphetamine-induced Stereotyped Behavior in Mice (Q36216477) (← links)
- Neurobiology of dopamine in schizophrenia (Q36756356) (← links)
- Glutamate and dopamine in schizophrenia: an update for the 21st century (Q36992322) (← links)
- Neurologic manifestations of chronic methamphetamine abuse. (Q37150547) (← links)
- What we know: findings that every theory of schizophrenia should explain. (Q37159625) (← links)
- Kraepelin and psychotic prodromal conditions (Q37179028) (← links)
- A neurocognitive animal model dissociating between acute illness and remission periods of schizophrenia (Q37212798) (← links)
- Synapsin III: role in neuronal plasticity and disease (Q37914375) (← links)
- Neurodegenerative aspects in vulnerability to schizophrenia spectrum disorders. (Q38209971) (← links)
- Presynaptic dopaminergic function: implications for understanding treatment response in psychosis (Q38219577) (← links)
- New Repeat Polymorphism in the AKT1 Gene Predicts Striatal Dopamine D2/D3 Receptor Availability and Stimulant-Induced Dopamine Release in the Healthy Human Brain (Q38729316) (← links)
- Stimulant and other substance use disorders in schizophrenia: prevalence, correlates and impacts in a population sample. (Q40190654) (← links)
- Longitudinal study of brain morphology in first episode schizophrenia (Q40718665) (← links)
- Individual differences in mood reactions to d-amphetamine: a test of three personality factors (Q40725033) (← links)
- Schizophrenia and substance abuse. (Q40825777) (← links)
- Detection of substance use disorders in severely mentally ill patients (Q40910554) (← links)
- Cocaine, Neuroleptics, and tardive dyskinesia as paleocortical escape (Q41291983) (← links)
- Dopaminergic sensitization: implications for the pathogenesis of schizophrenia (Q41389291) (← links)
- Leucocytosis in clozapine-treated patients as predictor of loss of treatment response? (Q41861177) (← links)